During 2026, a significant transformation is expected in the field of GLP-1 therapy. These drugs, which until now have been recognized for their high price, limited availability, and injectable use, such as Wegovy and Zepbound, could become more affordable and widely available. At the same time, alternative administration methods are being developed for people who want to avoid injections.
“Significant expansion of the GLP-1 therapeutic spectrum is expected, “announced Dr. Christopher McGowan, a gastroenterologist and founder of the Weight Management Clinic in Cary, North Carolina. “For the first time, the medical approach to obesity treatment is changing from a one-size-fits-all model to individualized therapeutic strategies.
Weight Loss Pills
The introduction of oral GLP-1 therapies for the regulation of body mass potentially represents one of the key steps forward in the modern pharmacological approach to obesity. Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for the first GLP-1 drug in tablet form for weight control, thus beginning a new chapter in the availability of this therapeutic option.
This preparation, known as the oral version of Wegovy therapy, is expected to become widely available soon. At the same time, an additional oral GLP-1 candidate from Eli Lilly is in the final stages of regulatory testing, indicating further market expansion in the near future.
According to available estimates, the introduction of oral formulations can significantly improve access to therapy, especially for patients who prefer the oral route or have faced limited availability of injectable formulations. At the same time, increased competition is expected to contribute to a gradual reduction of costs and greater economic accessibility.
The economic aspects are a key factor in expanding the use of these drugs. Projections indicate that monthly oral therapy may be more cost-effective than injectable forms. The lowest doses of the oral preparations are estimated at approximately $149 per month for uninsured patients, while higher doses run around $299.
On the other hand, the initial doses of injectable formulations are significantly more expensive. For patients with adequate health insurance, direct costs can be reduced, thereby increasing the availability of therapy.
However, clinical effects remain somewhat dose-dependent. The most pronounced loss of body mass was observed with higher doses, suggesting that a greater therapeutic effect may be associated with a greater financial burden.
Also, even lower prices can represent a barrier for some members of the population, which is why realistic expectations and an individualized approach to planning therapy are particularly important.
The specificity of oral GLP-1 drugs is also reflected in the mode of administration. For optimal therapeutic effect, strict adherence to the recommended protocol, including daily morning intake on an empty stomach, is crucial.
The results of the study indicate that disciplined application can lead to an average reduction in body weight of about 16.6%, whereas a lower effort, approximately 13.6%, is observed with weaker adherence. These data emphasize the crucial role of therapeutic discipline in achieving maximum efficiency.
Some newer oral candidates offer greater flexibility in timing of administration, which could improve adherence in daily practice. At the same time, experiences from clinical studies indicate that these drugs can not only reduce body weight but also improve energy levels and alter nutrition, suggesting a broader impact on patients’ lifestyles.
A Strong Injection
The Eli Lilly company is in the final phase of clinical development of Retatrutide, an experimental therapeutic drug that is increasingly being highlighted as potentially the most potent representative of the new generation of GLP-1-based therapies. Like other drugs in this class, including Wegovy and Zepbound, Retatrutide is given once a week as a subcutaneous injection.
It is characterized by simultaneous activation of GLP-1 and GIP receptors, with additional activation of the glucagon pathway, which distinguishes compared it from current therapies and may contribute to a more pronounced metabolic response.
Preliminary results from phase 3 clinical trials indicate high efficacy. Patients receiving the highest dose of Retatrutide achieved an average weight loss of approximately 29% after about 16 months, exceeding the results seen with available GLP-1 therapies. The study population included approximately 450 adult subjects with obesity or overweight, including patients with associated conditions such as osteoarthritis of the knee.
However, this pronounced therapeutic effect is accompanied by an increased risk of side effects. The most commonly reported symptoms include gastrointestinal complaints, including nausea, diarrhea, constipation, and vomiting.
The discontinuation rate was 18.2% in the active group, compared with 4% in the placebo group, suggesting potential tolerability challenges. In comparison, studies with Zepbound therapy had significantly lower discontinuation rates at the highest doses.
These findings suggest that increased pharmacological potency may not always align with clinical tolerability, especially in real-world settings, where adherence and individual tolerance are crucial in determining the final therapeutic outcome.
Nevertheless, Retatrutide is recognized as a potentially significant therapeutic option, especially in patients with severe forms of obesity in whom existing therapies do not lead to satisfactory results. Nevertheless, further evaluation of the safety profile remains crucial before its wider clinical implementation.
According to the information so far, the company is currently conducting additional clinical trials of this drug, with completion expected in 2026, while the approval process could occur in a relatively short time frame.
Prices and Partnerships
The availability of GLP-1 therapies for body mass regulation is expanding through the development of a direct payment model (self-pay/cash-pay), which is increasingly becoming a relevant mechanism for accessing these drugs outside traditional insurance systems.
The initial steps in this collection were taken in 2024, when Eli Lilly introduced the LillyDirect program, lowering prices for specific doses of the drug Zepbound for patients who finance the therapy independently.
This approach was soon replicated by Novo Nordisk, which, through the NovoCare Pharmacy platform, enabled the distribution of Wegovy therapy on more favorable terms for the same group of users.
In 2025, the direct payment model was further expanded to include large retail systems, making therapy more accessible. Retail chains such as Costco and Walmart have established commercial arrangements that enable uninsured patients to purchase GLP-1 drugs at predefined, lower prices.
Further development of this concept is expected in 2026 through the establishment of the digital platform TrumpRx.gov, which will serve as an intermediary connecting patients with official manufacturers offering discount programs. Although the platform will not directly distribute drugs, its importance is reflected in centralizing information and simplifying access to available options.
Preliminary estimates indicate that the monthly costs of therapies under such models could be about $350, with an expected decrease to approximately $250 in the future. At the same time, initial doses of oral GLP-1 preparations are projected at about $149 per month, further differentiating therapeutic options in terms of affordability.
However, it remains an open question whether the price reduction will be sufficient to make the therapy widely available to all patients for whom it is indicated. Although these models increase availability, the overall costs can still represent a significant barrier for a segment of the population.
An important aspect of these programs is their integration with telemedicine services, which enable remote evaluation of indications and the issuance of prescriptions. This approach can further facilitate initial access when insurance coverage is lacking.
However, the need for adequate professional supervision in the treatment process is highlighted. Increased availability must be accompanied by appropriate clinical guidance to ensure efficacy, safety, and long-term sustainability of therapeutic outcomes, particularly in the context of complex obesity management.
